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Purpose: Corneal inflammation associated with ocular adenoviral infection is caused by leukocytic infiltration of the
subepithelial stroma in response to expression of interleukin-8 (IL-8) and monocyte chemoattractant protein-1 (MCP-1)
by infected corneal cells. We have shown that these two chemokines are activated by the mitogen-activated protein kinases
(MAPKs) extracellular signal-regulated kinase (ERK) and p38 for IL-8, and Jun-terminal kinase (JNK) for MCP-1. It is
also well established that transcription of each of these chemokines is tightly controlled by the nuclear factor kappa B
(NFκB) transcription factor family. Therefore, we sought to better understand the differential regulation of chemokine
expression by NFκB in adenoviral infection of the cornea.
Methods: Primary keratocytes derived from human donor corneas were treated with signaling inhibitors and small
interfering RNA specific to MAPKs, and infected with adenovirus for different time periods before analysis. Activation
of specific NFκB subunits was analyzed by western blot, confocal microscopy, electromobility shift assay, and chromatin
immunoprecipitation, and chemokine expression was quantified by enzyme-linked immunosorbent assay.
Results: Upon adenoviral infection, NFκB p65, p50, and cREL subunits translocate to the nucleus. This translocation is
blocked by inhibitors of specific MAPK signaling pathways. Confocal microscopy showed that inhibitors of the p38, JNK,
and ERK pathways differentially inhibited NFκB nuclear translocation, while PP2, an inhibitor of Src family kinases,
completely inhibited NFκB nuclear translocation. Western blot analysis revealed that activation of specific NFκB subunits
was time dependent following infection. Chromatin immunoprecipitation experiments indicated that binding of NFκB
p65 and p50 subunits to the IL-8 promoter upon viral infection was differentially reduced by chemical inhibitors of
MAPKs. Electromobility shift assay and luciferase assay analysis revealed that transactivation of IL-8 occurred with
binding by the NFκB p65 homodimer or NFκB p65/p50 heterodimer as early as 1 h post infection, whereas MCP-1
expression was dependent upon the NFκB cREL but not the p65 subunit, and occurred 4 h after IL-8 induction. Finally,
knockdown of NFκB p65 by short interfering RNA abrogated IL-8 but not MCP-1 expression after adenoviral infection.
Conclusion: The kinetics of NFκB subunit activation are partly responsible for the observed pattern of acute inflammation
in  the  adenoviral-infected  cornea.  MAPKs  differentially  regulate  chemokine  expression  in  adenoviral  keratitis  by
differential and time-dependent activation of specific NFκB subunits.
An acute inflammatory response to infection or injury
occurs in stereotyped stages irrespective of invading organism
or mechanism of injury, with neutrophils being the first cells
to infiltrate the tissue or body cavity, followed shortly by
monocytes [1]. This pattern appears to be the result of the
specific  induction  and  activity  of  chemokines,  proteins
elicited  by  cells  that  induce  the  directed  migration  of
leukocytes into tissue sites of inflammation [2], by infected or
injured cells. Possible molecular mechanisms at play in the
tightly  controlled  pattern  of  acute  inflammation  include
transcriptional  induction,  transcriptional  repression,  and
mRNA stability. In particular, it has been shown that AU-rich
elements in mRNA contribute stability to the molecule and in
part  serve  to  control  the  kinetics  of  gene  expression  of
proinflammatory cytokines [3]. Leukocyte infiltration into the
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corneal stroma represents a critical pathogenic event in viral
infection of the cornea. Interleukin-8 (IL-8) is one of the
earliest chemokines to be expressed in infection and acts as a
first  line  of  defense  via  its  capacity  to  elicit  neutrophil
chemotaxis,  and  to  a  lesser  degree  monocyte  and  T-cell
chemotaxis [4-6]. IL-8 induction following viral infection has
been shown by many independent research groups [7-10], and
a wide variety of cells produce IL-8, including microglia and
astrocytes  [11-13].  However,  in  the  corneal  stroma  the
molecular  mechanisms  that  regulate  IL-8  expression
following  adenoviral  infection  remain  unclear.  Our  study
focuses on the kinetics of transcription of IL-8 and monocyte
chemoattractant protein 1 (MCP-1), another key chemokine
in  adenoviral  keratitis,  and  on  the  role  of  the  NFκB
transcription factor family in chemokine activation.
The nuclear factor-κB (NFκB) family of transcription
factors controls expression of well over one hundred genes,
the majority of which participate in regulating innate and
adaptive immunity [14,15]. Activation of NFκB occurs within
minutes  after  an  appropriate  stimulus  and  leads  to  strong
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2879transcriptional stimulation of both viral and cellular genes
[7,16-18].  Analysis  of  the  transcriptional  regulation  of
chemokines  induced  by  viral  infection  is  critical  to
understanding the pathogenesis of viral keratitis. However,
the mechanisms that connect viral infection to chemokine
expression by infected stromal cells are poorly understood
[7,19-22].
In general, chemokine gene expression is controlled by
the  NFκB  transcription  factor  family,  p65,  RELB,  cREL,
NFκB1  (p50/100),  and  NFκB2  (p52/105).  These  proteins
form  specific  homo-  or  heterodimers  for  transcriptional
activation of target genes in a cell-specific manner. NFκB
subunit  activation  can  be  achieved  through  two  main
pathways:  canonical  (classical),  characterized  by  the
activation of the IκB kinase (IKK) complex, including both
IKKα  and  IKKβ;  and  non-canonical  (non-classical),
characterized  by  activation  of  NFκB-inducing  kinase  and
IKKα, but not IKKβ [23-28]. Therefore, it is the specific
activation  of  upstream  IKKs  that  represents  the  point  of
divergence for NFκB activation. Activation of these pathways
has been determined to be both cell and stimulus specific
[26-28]. The canonical pathway is the route most commonly
activated  by  pathogens,  and  is  stimulated  by  pathogen-
associated  molecular  patterns  and  cytokines.  The  non-
canonical  pathway  has  been  described  particularly  in  B
lymphocytes, and is stimulated by B-cell activating factor,
lymphotoxin β, and CD40L [27,29]. Lipopolysaccharide from
Salmonella enterica was shown to activate both canonical and
non-canonical pathways in primary B cells with activation of
both  NFκB  p50/RELA  and  p52/RELB  heterodimers  [26].
Herpes simplex virus type 1 ICP27 protein was shown to
activate NFκB via the canonical pathway [30]. While the role
of NFκB in apoptosis following adenoviral infection has been
explored  [31],  its  role  in  cytokine  regulation  due  to  viral
infection has been less fully addressed.
We have earlier shown that NFκB p65 is activated upon
adenoviral infection in conjunction with the phosphoinositide
3-kinase/protein  kinase  B  (PI3K/AKT)  pathway  for  cell
survival during viral replication [31], but activation of NFκB
p65 as a possible mechanism for chemokine induction in
adenoviral infection has not been explored. Our prior studies
in  a  mouse  model  of  adenoviral  keratitis  have  shown
expression of KC (a homologue of IL-8 in the mouse) within
4 h of infection, followed by MCP-1 at 16 h post infection
[32]. In this report we address the role of specific NFκB
subunit  activation  in  the  kinetics  of  IL-8  and  MCP-1
expression in adenoviral-infected human corneal cells.
METHODS
Materials: Antibodies to p38, IKKα/β, NFκB p65, NFκB p50,
IκB,  cREL,  and  their  phosphorylated  counterparts  were
obtained from Cell Signaling Technology (Beverly, MA) and
Santa Cruz Biotechnology (Delaware, CA). The anti-human
IL-8 and MCP-1 antibodies and biotin-conjugated anti-human
IL-8  and  MCP-1  antibodies  were  obtained  from  BD
PharMingen (San Diego, CA). Inhibitors to p38 (SB203580),
JNK  (SP600125),  ERK  (PD98059),  and  Src  (PP2)  were
purchased  from  Calbiochem  (La  Jolla,  CA).  NFκB  p65-
specific and jumbled control siRNA were purchased from
Imgenex (San Diego, CA). The IL-8 luciferase construct was
a kind gift from Dr. R. Natarjan (Virginia Commonwealth
Univ). The luciferase measuring kit and Renilla constructs
were  purchased  from  Promega,  (Madison,  WI),  and  the
LightShift Chemiluminescent kit from Pierce (Rockford, IL).
Cell culture and viruses: Primary keratocytes were derived
from donor corneas as previously described [33]. Briefly, after
mechanical  debridement  of  the  corneal  epithelium  and
endothelium, corneas were cut into 2 mm diameter sections,
and each section placed in individual wells of 6-well Falcon
Tissue Culture Plates (Fisher Scientific, Pittsburgh, PA) with
Dulbecco’s Modified Eagle Medium (DMEM), containing
10% heat inactivated fetal bovine serum (FBS), penicillin G
sodium, and streptomycin sulfate. Corneal fragments were
removed prior to monolayer confluence. Cells were grown
and maintained at 37  oC in 5 % CO2. Cells from multiple
donors were pooled, and the cell monolayers used at passage
three.  For  inhibitor  analysis,  cells  were  pretreated  with
SB203580 (10 µM), SP600125 (25 µM), PD98059 (25 µM),
and PP2 (10 µM) at 37 °C for 3 h before infection, and were
exposed  to  the  inhibitors  at  the  same  concentrations
throughout  the  infection  process.  The  protocol  for  use  of
corneas from deceased human donors was approved by the
Massachusetts  Eye  and  Ear  Infirmary  Human  Studies
Committee, and conformed to the tenets of the Declaration of
Helsinki. Human adenovirus species D type 19 (HAdV-D19)
used in this study was cultured directly from the cornea of a
patient  with  EKC  [33],  and  purified  by  cesium  chloride
gradient. The virus was grown in human lung carcinoma cells
(A549 cells, CCL 185; American Type Culture Collection,
Rockville, MD) in Minimum Essential Media (MEM) with 2
%  FBS,  penicillin  G  sodium,  streptomycin  sulfate,  and
amphotericin B. The State of Oklahoma Department of Health
confirmed the viral serotype. Typical adenoviral cytopathic
effect, positive immunofluorescent staining for adenovirus
hexon proteins, and increasing titers of virus within one week
after infection of human corneal cells were seen (data not
shown).
Viral infection: Monolayer cell cultures were grown to 95%
confluence, serum starved overnight, inhibitor treated for 3 h
in Opti-MEM (Invitrogen, Carlsbad, CA), and infected at a
multiplicity of infection of 50 or mock infected with virus-free
dialysis buffer as a control.
Transfection: Transient transfections were done in 6 well
plates using FuGENE 6 (Roche, Indianapolis, IN) as per the
manufacturer’s  instructions.  A  total  of  2  μg  DNA  was
transfected, including NFκB p65 or control siRNA (Imgenex,
San  Diego,  CA),  IL-8  luciferase  construct,  and  pRL-TK
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internal control. The transfection mixture was prepared by
mixing 3 μl of FuGENE 6 in 47 μl of serum-free DMEM,
incubated at room temperature for 5 min, the DNA added, and
further incubated for 15 min, prior to transfection of 70–80%
confluent cells. Viral infections were carried out 48 h post-
transfection, and supernatants and cell lysates collected at
various  time  points  after  infection  for  enzyme-linked
immunosorbent  assay  (ELISA)  and  luciferase  assay,
respectively.
Immunoblot  analysis:  Adenoviral-  and  mock-infected
keratocytes were lysed with chilled cell lysis buffer (20 mM
Tris, pH 7.4, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1%
Triton  X-100,  2.5  mM  sodium  pyrophosphate,  1  mM  β-
glycerolphosphate, 1 mM Na3VO4, 1 μg/ml leupeptin, and 1
mM phenylmethylsulphonyl fluoride [PMSF]), and incubated
at  4  ºC  for  5  min.  The  cell  lysates  were  cleared  by
centrifugation  at  21,000×  g  for  15  min.  The  protein
concentration  of  each  supernatant  was  measured  by
bicinchoninic acid (BCA) analysis (Pierce, Rockford, IL) and
equalized.  Twenty  micrograms  of  cell  lysates  were
subsequently  separated  by  10%  sodium  dodecyl  sulfate
polyacrylamide  gel  electrophoresis  (SDS-PAGE)  and
transferred  onto  nitrocellulose  membranes  (BioRad,
Hercules, CA). The bands were visualized with an enhanced
chemiluminescence kit (Pierce, Rockford, IL).
Luciferase assay: Short interfering RNA (siRNA) transfected,
viral- or mock-infected cells were lysed with 500 μl of 1×
partial lysis buffer by rocking at room temperature for 15 min.
For the assay, 20 μl cleared cell lysate was added to 100 μl
luciferase assay reagent (Promega, Madison, WI), followed
by 100 μl Stop and Glo reagent (Promega) to measure renilla
luciferase  activity  as  an  internal  control.  IL-8  luciferase
activity was then normalized against renilla luciferase activity
and analyzed by one-way analysis of variance (ANOVA) with
preplanned contrasts, with α=0.05.
Enzyme-linked  immunosorbent  assay  (ELISA):  The  cell
supernatants were collected at various time points up to 4 h
post infection, and the levels of IL-8 and MCP-1 quantified
by sandwich ELISA. The detection limit was 30 pg/ml. Plates
were read on a SpectraMax M2 microplate reader (Molecular
Devices,  Sunnyvale,  CA)  and  analyzed  with  SOFTmax
analysis  software  (Molecular  Devices).  The  means  of
triplicate  ELISA  values  for  each  of  the  viral-  and  mock-
infected  wells  were  compared  by  one-way  ANOVA  with
preplanned contrasts, with α=0.05.
Electrophoretic  mobility  gel  shift  assay  (EMSA):  Nuclear
extracts from adenoviral- or mock-infected keratocytes were
prepared  using  Nucbuster  (Novagen,  Madison,  WI),  and
binding  and  supershift  assays  done  using  the  LightShift
Chemiluminescent  EMSA  kit  (Pierce),  according  to  the
manufacturers’  instructions.  Briefly,  chemokine  sense  and
antisense oligonucleotides encoding specific binding sites for
NFκB  were  synthesized  (IDT,  Coralville,  IA).
Oligonucleotides were then labeled using Biotin-ddUTP and
terminal transferase for 15 min at 37 °C in the labeling buffer
and then annealed. For the assay, 10μg of nuclear extract,
labeled oligonucleotide, poly (dI-dC; 1 μg), and poly L-lysine
(0.1 μg) were mixed in the binding buffer and incubated at
room temperature for 15 min. For comparison, 100 molar
excess of unlabelled probe was added to the reactions 15 min
before the addition of labeled probe. For the supershift assay,
1 or 2 μg antibody to NFκB p65, p50, or cREL was added to
the binding reaction and incubated on ice for 30 min. Protein-
DNA complexes were resolved in 5% pre-electrophoresed
polyacrylamide  gel  in  0.5×  TBE  running  buffer  and  then
transferred to a nylon membrane (Roche, Indianapolis, IN).
The membrane was then probed for anti-biotin and the bands
were detected by chemiluminescence using Kodak films and
developed in a QCP X-Ray film processor in which each film
is exposed for a preset time. Densitometric analysis of EMSA
was performed using ImageQuant 5.2 (Pierce, Rockford, IL)
in the linear range of detection, and absolute values then
normalized to binding in mock-infected cells. The means of
normalized replicate EMSA values for each condition were
compared by one-way ANOVA with preplanned contrasts,
with α=0.05.
Confocal microscopy: Keratocytes grown on chamber slides
(Nunc, Rochester, NY) were treated with dimethyl sulfoxide
or inhibitor for 3 h and then infected with adenovirus or
dialysis buffer for 20 min. Cells were partially fixed in 0.05%
paraformaldehyde for 10 min, washed in PBS containing 2%
FBS, and permeabilized in solution containing 0.1% Triton
X-100 for 5 min. After 30 min blocking in 3% FBS-PBS, the
cells were incubated in 5 μg/ml of NFκB p65, p50, and cREL
primary antibody for 1 h at room temperature, washed, and
incubated in Alexafluor-594 and Alexafluor-488 conjugated
secondary antibody (Molecular Probes, Eugene, OR) for 1 h
more at room temperature. Cells were then washed, fixed in
2%  paraformaldehyde,  and  mounted  using  Vectashield
(Vector labs, Burlingame, CA) mounting medium containing
DAPI. Images were taken with an Olympus FluoView 500
confocal microscope using a 60× water immersion objective.
Chromatin immunoprecipitation (ChIP): For ChIP, inhibitor
treated and viral- or mock-infected cells were subjected to
cross-linking  for  10  min  in  1%  formaldehyde  at  37  °C,
incubated with 0.125 M glycine for 5 min, and then washed
twice  in  cold  PBS  containing  protease  inhibitors  before
resuspension in sodium dodecyl sulfate (SDS) lysis buffer
(1% SDS, 10 mM EDTA, 50 mM Tris; pH 8), also containing
protease inhibitors. After incubation on ice for 10 min, the
suspension was sonicated to reduce the DNA lengths to 200–
1,000 bp, centrifuged at 4 °C for 10 min, and the supernatant
used  for  immunoprecipitation.  Sonicated  extracts  were
precleared  with  protein  A/G  beads  (Santa  Cruz
Biotechnology, Santa Cruz, CA) plus 50 μg salmon sperm
DNA for 30 min at 4 °C before incubation with either anti-
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Immunocomplexes were precipitated with blocked protein A/
G beads for 1 h. The beads were washed once in low-salt
buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM
Tris,  150  mM  NaCl;  pH  8),  once  in  high-salt  buffer
(containing 500 mM NaCl), once in LiCl buffer (0.25 M LiCl,
1% NP-40, 1% sodium deoxycholate, 1 mM EDTA, 10 mM
Tris; pH 8), and twice in Tris-EDTA buffer. DNA-protein
complexes were eluted with 0.1 M NaHCO3 and 0.2% SDS,
and cross-linking was reversed by incubation at 65 °C for 4 h.
Proteinase K (10 μg; Invitrogen, Carlsbad, CA) and 2 μl of
DNase-free RNase A (10 mg/ml; Roche) were added for 2 h
at  50  °C.  The  remaining  immunoprecipitated  DNA  was
phenol-chloroform  purified  and  subjected  to  PCR  using
specific IL-8 and MCP-1 primers. Of the total lysate, 5% was
used as a loading control.
RESULTS
Activation of NFκB subunits and their inhibitory kinase (IκB)
in adenoviral infection: In the absence of stimulation, NFκB
components  are  sequestered  in  the  cytoplasm  by  a  tight
association with inhibitory proteins of the IκB family. Upon
stimulation,  IκB  is  phosphorylated  by  IKK-containing
complexes, releasing NFκB subunits and leading ultimately
to  the  degradation  of  IκB  via  the  ubiquitin-proteosome
pathway [27], and translocation of NFκB to the nucleus for
specific  transcriptional  activity.  We  infected  human
keratocytes for 1 and 4 h and performed immunoblot analysis
for phosphorylation of specific NFκB subunits, IKKα/β, and
IκB. After 1 h, adenoviral infection induced phosphorylation
of NFκB p65 and p50, IKKα/β, and IκB but not cREL (Figure
1A). Phosphorylation of p65, IKKα/β, and IκB was reduced
by inhibitors of p38 MAPK (SB203580), ERK (PD), and Src
(PP2; Figure 1A). However, the JNK inhibitor (SP600125)
only partially reduced the activation of NFκB p65, IKKα/β,
and IκB, consistent with our previous observation that these
MAPK  have  different  downstream  targets  in  adenoviral-
infected cells [7,8,34], possibly because JNK is not involved
in IL-8 induction. At 4 h post infection, we observed increased
cREL phosphorylation in viral-infected cells as compared to
mock-treated cells (Figure 1B). These results indicate that
IκB and members of the NFκB family are activated rapidly
upon  adenoviral  infection,  and  that  their  activation  is
dependent  on  upstream  kinases  shown  previously  to  be
important to chemokine expression by adenoviral-infected
cells [7,8].
IL-8 and MCP-1 promoter binding activity of NFκB subunits
in adenoviral infection: In general, NFκB transcription factors
are activated rapidly after exposure to viral infection, resulting
in a strong transcriptional regulation of a multitude of early
viral  and  cellular  genes  [35].  We  previously  reported  the
activation of NFκB p65 in a PI3K/AKT dependent manner
upon adenoviral infection that ensured delayed cell death and
promoted  viral  replication  [31].  EMSA  performed  on
adenoviral-infected keratocytes at 1 h post infection showed
NFκB binding to the IL-8 promoter as distinguished from
Figure 1. Activation of NFκB subunits
upon adenoviral infection in keratocytes
is shown. Whole cell extracts from 1 h
post viral-infected (V) or mock-treated
(M)  cells,  pretreated  with  signaling
inhibitors  SB203580  (SB:  p38),
SP600125  (SP:  JNK),  PD98059  (PD:
ERK), or PP2 (Src) were run on a 10%
sodium dodecyl sulfate polyacrylamide
gel electrophoresis and immunoblotted
using  anti-phospho-NFκB  p65,  NFκB
p50, cREL, IKKα/β and IκB antibodies.
Viral-infected  cells  showed  increased
activation  of  NFκB  p65,  NFκB  p50,
IKKα/β and IκB both at (A) 1 h and (B)
4  h  after  infection.  cREL
phosphorylation was unchanged at 1 h,
but increased at 4 h post infection. Actin
levels to determine equivalent protein
loading are shown. Phosphorylation of
p65, IKKα/β, and IκB was reduced by
SB, PD, and PP2 but SP only partially
reduced  the  activation  of  NFκB  p65,
IKKα/β,  and  IκB  (A).  At  4  h  post
infection,  cREL  phosphorylation  in
viral-infected cells was reduced by all
inhibitors used (B).
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2882mock infection (Figure 2A). In viral-infected cells, antibody
specific to each NFκB subunit appeared to reduce binding, as
indicated  by  reduced  density  of  the  primary  band,
demonstrating  the  possible  involvement  of  NFκB
homodimers or heterodimers in the activation of IL-8 gene
expression. Specificity of probe binding was shown by use of
100 molar excess of unlabelled probe (data not shown). We
have previously shown that chemical inhibition of JNK has
no  effect  on  IL-8  expression  by  adenoviral-infected
keratocytes. Similarly, the JNK inhibitor appeared to have no
effect on NFκB binding to the IL-8 promoter, while inhibitors
of p38, ERK, and Src reduced NFκB binding (Figure 2A).
Statistically, overall binding was significantly greater in viral-
infected cells as compared to mock-infected cells (Figure 2B,
p<0.0001,  ANOVA).  IL-8  promoter  binding  of  NFκB
subunits  was  significantly  reduced  by  all  four  inhibitors
(p<0.05). Antibody binding/shift on the IL-8 promoter was
not observed in mock-treated cells or in cells treated with any
inhibitor prior to infection (Figure 2B, p>0.05). These data
correlated with our western blots (Figure 1) and our previous
observation that JNK regulates expression of MCP-1 but not
IL-8 [34].
At 1 h after infection, we did not observe significant
binding of NFκB subunits to the MCP-1 promoter (Figure
2C). However, at 4 h post infection, NFκB subunit binding to
the  MCP-1  promoter  was  significantly  greater  in  viral-
infected cells as compared to mock-infected cells (p<0.0001).
All 3 subunits, but in particular cREL, bound to the MCP-1
promoter at 4 h after infection (Figure 2C), indicating that IL-8
and MCP-1 may be regulated at different time points and by
different NFκB dimers. We occasionally but not consistently
observed  low  levels  of  NFκB  p65  binding  to  the  MCP-1
promoter (data not shown). By graphical analysis of multiple
EMSA  experiments,  for  MCP-1,  only  the  JNK  inhibitor
reduced binding, consistent with a JNK-specific activation
pathway for MCP-1 (Figure 2D, p<0.05). For the MCP-1
Figure 2. IL-8 promoter binding activity of NFκB subunits is reduced by specific inhibitors. A: EMSA was done using 10 μg nuclear extracts
after 1 h of viral (V) or mock (M) treatment in cells pretreated with signaling inhibitors SB203580 (SB: p38), SP600125 (SP: JNK), PD98059
(PD: ERK), or PP2 (Src). Binding of p65 to the IL-8 promoter appeared greater in viral-infected cells (lane 1) as compared to mock-treated
cells (lane 5), and was reduced in cells pretreated with SB (lane 9) and PP2 (lane 21), but not with SP (lane 13) or PD (lane 17). Supershift
assays with NFκB p65, p50 and cREL revealed more shift in viral-infected and SP-treated cells (lanes 2–4 and 14–16), but reduced shift or
no shift in mock-treated (lanes 6–8) or other inhibitor-treated cells: SB (lanes 10–12), PD (lanes 18–20), and PP2 (lanes 22–24). B: Graphic
representation of five independent EMSA experiments. Overall binding was significantly greater in viral-infected cells as compared to mock-
treated cells (p<0.0001, ANOVA). IL-8 promoter binding of NFκB subunits was significantly reduced by all four inhibitors (p<0.05). Antibody
binding/shift on the IL-8 promoter was not observed in mock-treated cells or in cells treated with any inhibitor prior to infection (p>0.05).
C: EMSA done for MCP-1 at both 1 and 4 h post infection. Viral infection induced binding/shift relative to mock infection only at 4 h post
infection (lanes 1 and 5). Binding at 4 h post infection was reduced in mock-treated and inhibitor-pretreated groups (lanes 5–24). At 4 h post
infection, antibody to p50 and cREL reduced binding (lanes 3 and 4), but antibody to p65 (lane 2) did not. D: Graphical representation of five
independent EMSA experiments for MCP-1 at 4 h post infection. Overall binding was significantly greater in viral-infected cells as compared
to mock-treated cells at 4 h post infection (p<0.0001, ANOVA). Binding was reduced in viral-infected cells only by SP (p<0.05). No shift
was seen in mock-infected cells due to addition of antibody. In viral-infected cells, a statistically significant shift was seen with p50 and cREL
(p<0.05), but not with p65. In viral-infected inhibitor-treated cells only SP reduced binding (p<0.05).
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2883promoter,  a  binding/shift  was  seen  with  p50  and  cREL
(p<0.05), but not with p65 (p>0.05), suggesting that NFκB
p65 does not participate in MCP-1 transcription. In light of
our in vivo data showing that KC, an IL-8 homolog, is the first
chemokine to be induced upon adenoviral-infection, and that
MCP-1 expression is delayed, these results indicate that in
adenoviral infection, IL-8 is transactivated by NFκB p65/p65
homodimers  and/or  NFκB  p65/p50  heterodimers,  while
MCP-1 gene expression is delayed and uses predominantly
cREL and NFκB p50.
Cellular  localization  of  NFκB  subunits  in  adenoviral
infection:  NFκB  and  IκB  shuttle  continually  between  the
cytoplasm and nucleus in steady state conditions, resulting in
a  basal  level  of  NFκB  activity  [36].  We  previously
demonstrated  increased  nuclear  localization  of  NFκB  p65
upon  adenoviral  infection  [7].  Now,  using  confocal
microscopy, we confirmed increased nuclear localization of
Figure 3. Nuclear translocation of NFκB subunits upon viral infection. Confocal microscopy shows cellular localization of NFκB subunits.
A: Cytoplasmic localization of NFκB p65 (yellow) is compared to nuclei (blue, DAPI stain) in mock-infected keratocytes (M). Adenoviral-
infected (V) keratocytes demonstrate nuclear localization of NFκB p65 and p50. Nuclear translocation of NFκB p65 was reduced in the
presence of inhibitors of p38 (SB) and ERK (PD). The nuclear localization of both NFκB p65 and p50 was partially reduced upon pretreatment
with an inhibitor of JNK (SP) and completely blocked with an inhibitor of Src (PP2). Isotype control is shown (Ctrl). Viral infection also
induced nuclear translocation of cREL (B), while all signaling inhibitors tested reduced the nuclear translocation of cREL.
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2884NFκB subunits in viral- but not mock-infected cells (Figure
3A).  MAPK  inhibitors  partially  impaired  the  nuclear
localization of NFκB p65, p50, and cREL in viral-infected
cells (Figure 3A). Interestingly, SP600125 had less inhibitory
effect  on  nuclear  localization  compared  to  other  MAPK
inhibitors, indicating that the JNK pathway does not mediate
NFκB  p65  activation.  The  Src  inhibitor  PP2  completely
suppressed NFκB p65 and p50 nuclear translocation (Figure
3A),  suggesting  a  broad  upstream  role  of  Src  in  these
pathways,  while  downstream  MAPKs  collaborate  in  the
activation and translocation of NFκB. Confocal microscopy
was also performed for the cREL subunit of NFκB. In these
experiments, cREL and p65 were both translocated into the
nucleus  upon  viral  infection  (Figure  3B)  as  compared  to
mock-treated cells (Figure 3B). Pretreatment with signaling
inhibitors of Src and MAPK reduced both p65 and cREL
nuclear translocation, except for SP600125 (Figure 3B).
Specific NFκB subunits bind to the IL-8 and MCP-1 promoters
upon  viral  infection  in  a  time-dependent  fashion:  The
presence of NFκB in the nucleus is not by itself a direct
indication of transcriptional activity [36]. To confirm whether
translocated NFκB p65 is transcriptionally active upon viral
infection, we analyzed the binding of NFκB p65 and p50 to
the IL-8 or MCP-1 promoter using a ChIP technique. Binding
of  both  NFκB  p65  and  p50  on  the  IL-8  promoter  was
considerably increased with adenoviral infection, well above
the basal levels seen in mock-treated cells at 1 and 4 h post
infection  (Figure  4A).  As  expected,  inhibitors  of  Src  and
MAPKs dramatically reduced NFκB p65 and p50 binding.
Anti-mouse serum control demonstrated the specificity of
NFκB p65 and p50 antibody binding, as the control antibodies
did not pull down IL-8 DNA. IL-8 promoter binding appeared
similar at 1 and 4 h post infection. cREL binding to the IL-8
promoter was negligible. Interestingly, no NFκB p65 was
bound to the MCP-1 promoter at 1 or 4 h post infection (Figure
4B).  NFκB  p50  binding  to  the  MCP-1  promoter  was
equivalent at both 1 and 4 h after infection and was unaffected
by MAPK inhibitors. A marginal increase in cREL binding to
the  MCP-1  promoter  was  apparent  at  1  h  post  infection,
increasing dramatically at 4 h after infection. cREL binding
at 4 h was reduced by all inhibitors utilized.
Figure 4. Analysis of promoter binding
activity by NFκB subunits using ChIP
assay. ChIP was performed with 200 μg
lysate. A: Binding of NFκB p65 and p50
was observed at both 1 and 4 h post
infection on the IL-8 promoter (left and
right panels, respectively). A negligible
amount  of  cREL  bound  to  the  IL-8
promoter  at  1  and  4  h.  Inhibitor
pretreatment  reduced  the  binding  of
p65,  p50,  and  cREL  on  the  IL-8
promoter  at  both  time  points  post
infection.  For  ChIP,  5%  of  the  total
lysate  was  used  as  a  loading  control
(Load)  to  show  that  an  equivalent
amount  of  extract  was  subjected  to
immunoprecipitation. Isotype control is
shown  (Ctrl).  B:  p65  binding  to  the
MCP-1 promoter was not observed at 1
or  4  h  post  infection.  p50  bound  but
showed no apparent change across the
pretreatment groups at 1 or 4 h. Binding
of cREL on the MCP-1 promoter was
apparent  at  1  h  but  increased
dramatically at 4 h post infection.
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2885NFκ-B  p65  is  critical  for  IL-8  induction  in  adenoviral
infection: Given that adenoviral infection induces NFκB p65
translocation, transcriptional activation, and IL-8 promoter
binding, we wished to determine whether p65 is essential to
IL-8 induction in adenoviral-infected cells. We used NFκB
p65-specific  or  scrambled  control  siRNA  for  these
experiments.  Figure  5A  shows  successful  knockdown  of
NFκB p65 expression in keratocytes to 70– 80% in repeat
experiments (data not shown). When co-transfected with IL-8
luciferase construct, NFκB p65 specific siRNA reduced IL-8
luciferase activity to basal levels at all time points tested post
infection  (Figure  5B,  p<0.0001),  while  scrambled  control
siRNA demonstrated no such effect. Interestingly, MCP-1
ELISA performed on supernatants from the same experiments
(Figure  5C)  showed  no  reduction  in  MCP-1  protein
expression in p65 siRNA treated cells, indicating that NFκB
p65 is dispensable for MCP-1 induction. MCP-1 expression
became significantly elevated in viral-infected cells only at 4
h  post  infection  (p<0.0001).  siRNA  against  p65  did  not
significantly alter MCP-1 protein expression in viral-infected
cells at any time post infection.
DISCUSSION
The observed difference in the kinetics of IL-8 and MCP-1
chemokine  expression  after  adenoviral  infection,  in  the
studies herein, correlates well with the pattern of leukocyte
infiltration in vivo [32], but in general, the mechanisms for
differential  expression  of  proinflammatory  cytokines  in
infection are not well understood. The stepwise order and
timely expression of various inflammatory mediators seem to
be preset as a part of a master gene activation program. For
example,  the  consistent  differential  in  time  between  the
expression  of  interferon  gamma  and  IL-17  during  active
experimental autoimmune encephalitis in DA rats suggests
different roles for these cytokines in the pathogenesis of the
disease [37]. Our data is consistent with the idea that the
kinetics of cytokine expression in inflammation are due in
large part to the interplay between elements that regulate
transcriptional  induction,  transcriptional  repression,  and
perhaps mRNA stability [3].
Two decades after the initial discovery of NFκB, new
functions  for  this  ubiquitous  transcription  factor  family
continue to emerge. Recent progress in understanding how the
immune system senses and responds to pathogens has drawn
new attention to NFκB as a key effector of inflammatory
responses to infection [27]. Its multiple actions, redundancy
in function, and cell specificity have made building a picture
of  the  molecular  mechanisms  by  which  NFκB  activates
cytokine genes in infection a complex undertaking. Viruses
that have been previously shown to activate NFκB include
human immunodeficiency virus [38], hepatitis B virus [39],
hepatitis  C  virus  [40,41],  Epstein  Barr  virus  [42],  herpes
simplex virus [43], and influenza virus [44]. The K13 protein
of  human  herpes  virus-8  was  shown  to  mediate  IL-8  via
NFκB p65, p50 and cREL [10]. Most prior studies of the
influence of adenoviral infection on NFκB activation used
either  recombinant  adenoviruses  [45],  adenovirus  vectors
[46,47],  or  isolated  adenovirus  proteins  [7,45,48,49].  The
possible  roles  of  NFκB  binding  kinetics  and  subunit
specificity in chemokine expression by primary keratocytes
Figure 5. NFκB p65 is indispensable for IL-8 but dispensable for
MCP-1  induction.  A:  A  representative  western  blot  showed
knockdown  of  NFκB  p65.  B:  A  luciferase  assay  demonstrates
reduction  of  IL-8  transcription  to  mock  levels  at  all  times  post
infection by p65 siRNA treatment (p<0.0001). C: MCP-1 ELISA
revealed  statistically  increased  expression  at  4  h  post  infection
(p<0.0001),  but  transfected  siRNA  specific  to  p65  did  not  alter
MCP-1 expression, as compared to scrambled control siRNA.
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2886infected with a native adenovirus have not been previously
studied.
Many  previous  reports  demonstrate  IL-8  induction
through various MAPK pathways converging on NFκB [11,
41],  and  binding  of  NFκB  p65  to  the  IL-8  promoter  [7,
50-53].  In  our  studies,  adenoviral-infected  cells  showed
increased nuclear translocation and IL-8 promoter binding for
NFκB  p65  and  p50.  Interestingly,  we  demonstrated  by
confocal microscopy, EMSA, and western blot that the JNK
inhibitor (SP600125) had a minimal effect on NFκB p65 and
p50 binding to IL-8 promoter. These data correlate with our
earlier  reports  showing  that  inhibition  of  JNK  activity  in
adenoviral-infected cells did not reduce IL-8 expression [34]
or inhibit NFκB p65 translocation to the nucleus [7]. However,
the ChIP data did appear to show an effect of SP600125 on
p65. Also, cREL binding to IL-8 promoter by ChIP assay was
negligible, but our supershift assay with cREL on the IL-8
promoter was significant. Further studies will be necessary to
resolve these apparent discrepancies.
Our confocal microscopy data demonstrated increased
nuclear  translocation  of  NFκB  p65,  cREL,  and  p50  in
adenoviral-infected cells, whereas no such translocation was
observed  in  mock-treated  cells.  By  confocal  microscopy,
inhibitors to various MAPKs reduced but did not completely
inhibit NFκB subunit translocation to the nucleus, suggesting
that NFκB nuclear translocation represents a summation of
upstream activity by numerous kinases. Our earlier studies
demonstrated that inhibition of Src fully blocked activation of
p38 MAPK, ERK, and JNK (32, 35, and 52), suggesting that
Src kinases are linearly upstream to all 3 MAPKs. By confocal
microscopy, inhibition of Src also effectively blocked NFκB
nuclear translocation.
Although IL-8 is one of the best-studied chemokines in
host–pathogen  interactions,  the  specific  signaling  and
molecular mechanism underlying the kinetics of its induction
remain  to  be  fully  elucidated.  IL-8  contributes  to  the
chemotaxis of neutrophils but also other leukocytes [11-13],
and  has  become  a  paradigm  chemokine  for  translational
studies of anti-chemokine therapy. Monoclonal antibody to
IL-8  was  recently  utilized  successfully  as  a  treatment  for
localized pustular psoriasis [54]. Our data clearly show that
NFκB p65 is critical for IL-8 expression, as knockdown of
p65 reduced IL-8 luciferase activity to mock levels at multiple
time  points  post  infection.  Reduced  p65  did  not  inhibit
expression  of  MCP-1,  suggesting  again  that  MCP-1
expression  is  not  NFκB  p65  dependent.  We  suggest  that
NFκB p65 and cREL play a role in the kinetics of IL-8 and
MCP-1 gene regulation, respectively, in adenoviral-infected
primary keratocytes. Further studies are needed to clarify the
molecular mechanisms underlying MCP-1 induction and how
other  transcription  factors  such  as  Sp1  may  regulate
chemokine induction in adenoviral infection.
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